Kornimate/medical-research-clean huggingface dataset:
a yoga and wellness program for breast cancer survivors with persistent fatigue

Conditions: Breast Cancer; Fatigue

Summary: this randomized controlled trial will compare the effectiveness of an iyengar yoga intervention to a wellness seminar health education lecture series, for improvements in energy, mood and biological functioning in breast cancer survivors with persistent, post-treatment fatigue. it is anticipated that the iyengar yoga intervention will be feasible and acceptable to breast cancer survivors with minimal side effects and that the yoga intervention will be effective in improving fatigue and physical performance.

fatigue is the most common and distressing side effect of cancer treatment and persists beyond successful treatment completion in approximately 30% of breast cancer survivors, causing serious disruption in quality of life. behavioral interventions incorporating physical activity or relaxation/stress management have demonstrated beneficial effects on cancer-related fatigue, although research in cancer survivors is limited. mind-body interventions such as yoga are extremely popular among cancer patients and offer a promising alternative to traditional treatments. research is needed to establish the feasibility and efficacy of these interventions in cancer populations, particularly those who are experiencing problems with fatigue.

Eligibility criteria:
inclusion criteria: * diagnosed with early, resectable breast cancer (stage i or ii) * completed treatment with surgery, radiation, and/or chemotherapy between 6 months and 5 years previously * no other cancer in last 5 years, including breast cancer recurrence * postmenopausal women * age 40 - 65 * reporting persistent cancer-related fatigue exclusion criteria: * evidence that fatigue is directly related to a medical or psychiatric disorder (e.g., untreated hypothyroidism, diabetes, anemia (defined as hematocrit \< 24), chronic fatigue syndrome, current major depression, insomnia, sleep apnea, restless leg syndrome) * evidence that fatigue is related to other non-cancer related factors (e.g., shift work, recent change in activity or schedule) * physical problems or conditions that could make yoga unsafe (e.g., serious neck injuries, unstable joints; also severe cachexia, dizziness, bone pain, severe nausea, etc) * regular use of medications and/or behavioral therapies that would confound evaluation of iy, including regular participation in yoga classes * presence of medical conditions that involve the immune system and would confound immune evaluation (e.g., autoimmune disorder, inflammatory disease) * use of medications that might confound immune evaluation (e.g., regular use of corticosteroids, narcotics, opiates) * unable to commit to intervention schedule * body mass index greater than 30 kg/m2 * regular tobacco (defined as daily or near daily) or alcohol use (defined as \> 2 drinks/day)

Keywords: breast cancer fatigue proinflammatory cytokines physical functioning quality of life
does pre and postoperative dextromethorphan reduce post-tonsillectomy pain in children?

Conditions: Pain, Postoperative

Summary: with institutional ethics board and health canada approval, pediatric patients (ages 3-12) undergoing tonsillectomy or adenotonsillectomy (under standardized anesthesia) will be randomized to receive dextromethorphan hydrobromide (1mg/kg orally) 30 min preoperatively and again 8 hours postoperatively or placebo (syrup identical in taste, appearance and volume) at the same time points. the primary outcome is an integrated assessment of perioperative pain scores and opioid use for 24 hours postoperatively. secondary outcomes include nausea, vomiting, respiratory depression, and bleeding for 24 hours postoperatively. our hypothesis is that dextromethorphan will decrease the incidence/severity of post-tonsillectomy pain. the improved pain control will be apparent through reduced opioid consumption and integrated pain scores. this will result in a reduced incidence of opioid-related side effects and adverse events.

with institutional ethics board and health canada approval and parental consent and child assent, pediatric patients (ages 3-12) undergoing tonsillectomy or adenotonsillectomy (under standardized anesthesia) will be randomized to receive dextromethorphan hydrobromide (1mg/kg orally) 30 min preoperatively and again 8 hours postoperatively or placebo (syrup identical in taste, appearance and volume) at the same time points. the primary outcome is an integrated assessment of perioperative pain scores and opioid use for 24 hours postoperatively. pain scores were collected preoperatively at rest and then at 1,2,3,8,9,10 and 24 hours postoperatively using the validated children's hospital of eastern ontario pain scale (cheops). secondary outcomes include nausea, vomiting, respiratory depression, and bleeding recorded by blinded observers for 24 hours postoperatively. our hypothesis is that dextromethorphan will decrease the incidence/severity of post-tonsillectomy pain. the improved pain control will be apparent through reduced opioid consumption and integrated pain scores. this will result in a reduced incidence of opioid-related side effects and adverse events.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologist's (asa) physical classification i and ii * tonsillectomy or adenotonsillectomy * admission to extended postoperative care unit exclusion criteria: * use of monoamine oxidase inhibitors, serotonin reuptake inhibitors or tricyclic antidepressants * requirement of preoperative sedation * recent dextromethorphan use (\<24 h before surgery) * intolerance, sensitivity or contraindication to any agents used in the study * pre-existing chronic pain or chronic analgesic use * body mass index (bmi) for age percentile greater than 90 * confounding procedural factors which might affect the validity of the data * inability to adhere to study protocol * contraindication to volatile anesthetics

Keywords: opioid analgesics, opioid consumption adverse effects postoperative pain tonsillectomy
action of amantadine on post-stroke aphasic patients

Conditions: Cerebral Infarction

Summary: the objective of the study is to test the action of the amantadine, as dopa-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic patients.

in france, there are around 30000 aphasic patients. the actual taking care of these patients after stroke includes the treatment of acute stage in stroke unit, followed by rehabilitation program. however, most non fluent aphasic patients remain chronically handicapped despite of intensive logopedic training. the objective of this clinical project is to test the action of pharmacologic agents on verbal fluency of aphasic patients victims of cerebral infarctions. only a few studies have been done with various pharmacologic agents, and although the results were not clearly conclusive, they were sufficiently positive for suggesting to launch a well controlled randomized cross-over study. then the objective of study is to test the action of the amantadine, as dopa-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic patients.

Eligibility criteria:
inclusion criteria: * rankin \< 3 * \> 18 years and \< 75 * francophone * within cognitive deficit known before stroke * stroke, single in sylvian artery area * aphasia " non fluent " following a stroke * stroke \> six month * stable treatment exclusion criteria: * rankin \> 3 * non francophone * do not read nor write * many stroke - against indication * participated in another clinical trial * deaf or blind * intercurrent disease * new treatment (\< 2 months) cognitive * pregnant or lactating

Keywords: cerebral infarction
impact of home-based rehabilitation on motor function and mood in individuals with disabilities

Conditions: Musculoskeletal Diseases; Neurological Diseases

Summary: this study aims to evaluate the impact of a multidisciplinary home-based rehabilitation program on motor function and mood in individuals with moderate neuromusculoskeletal disabilities. participants will receive personalized treatment plans over four months, including sessions in physical therapy, occupational therapy, nutrition, psychology, nursing, and podiatry. the study will measure motor function using the berg balance scale and mood using the beck depression inventory. this program will be conducted in the magallanes region of chile, involving participants recruited from the national disability registry.

this study is designed to assess the effectiveness of a comprehensive home-based rehabilitation program for individuals with moderate neuromusculoskeletal disabilities. the intervention will include a multidisciplinary approach, involving a team of healthcare professionals who will provide a range of services tailored to each participant's needs. the services will include 32 sessions of physical therapy, 8 sessions of occupational therapy, 4 sessions of nutrition counseling, 8 sessions of psychological support, and 4 sessions of nursing and podiatry care. the intervention will span four months, with a total of 82 hours of therapy per participant. participants will be evaluated at the beginning and end of the program using the berg balance scale to measure motor function and the beck depression inventory to assess mood. the study aims to demonstrat improvements in motor function and balance, with a reduction in fall risk, and to explore changes in depression levels among the participants. quality assurance procedures will include standardized training for all healthcare professionals involved, regular monitoring of therapy sessions, and adherence to established protocols for data collection and analysis. this study highlights the potential benefits of home-based rehabilitation programs and underscores the need for further research to explore long-term outcomes and additional measures to enhance patient well-being.

Eligibility criteria:
inclusion criteria: * individuals with moderate neuromusculoskeletal disabilities. * participants referred by recognized medical institutions. * able to provide informed consent. exclusion criteria: * individuals with severe cognitive impairments that hinder their ability to follow the rehabilitation program. * participants with acute medical conditions that require immediate hospitalization. * pregnant women.

Keywords: musculoskeletal disabilities neurological disabilities berg balance scale beck depression inventory multidisciplinary rehabilitation home-based care physical rehabilitation mental health assessment fall risk reduction patient-centered care
prospective longitudinal all-comer inclusion study in eating disorders

Conditions: Anorexia Nervosa; Bulimia Nervosa; Binge-Eating Disorder; Eating Disorder NOS

Summary: the proled study is a prospective and longitudinal study of patients with eating disorders. annual interviews and collection of biological samples are done, as well as during changes in disease course e.g. during hospitalization. included are qualitative interviews, psychometric tests, questionnaires which are used to collect data on psychopathology. there is also collection of blood, urine and faeces.

the objective is to increase the understanding of the psychopathology and pathophysiology of eating disorders. more specifically, the aim is to identify biomarkers that relate to prognosis, disease course and response to treatment as usual of eating disorders, and, to improve the understanding of the pathophysiology of eating disorders in order to identify novel molecular targets for treatment. rationale the etiology of eating disorders (ed's) is unknown. previous studies have identified genes that link anorexia nervosa to other psychiatric (e.g. schizophrenia) and somatic disorders (e.e. diabetes). association studies have also suggested genetic causes underlying bulimia nervosa and binge eating disorders. the proled study aims to improve the understanding of both the psychopathology and pathophysiology of eating disorders. no experimental drug will be used in this study. there is a great need for an increased biological understanding of ed's in view of the prevalence, the costs, the severity and high mortality rates, and the lack of efficient treatments. the proled study aims to answer questions related to these unmet medical needs. the study design is prospective and longitudinal. qualitative interviews, psychometric tests, questionnaires are used to collect data on psychopathology. there is also collection of blood, urine and faeces.

Eligibility criteria:
inclusion criteria: * eating disorder (icd-10) exclusion criteria: * forced care/non-voluntary

Keywords: eating disorders psychopathology pathophysiology prospective longitudinal
injection technique in subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: since pain is usually accompanied by a substantial effect on daily life that results in the extensive use of healthcare resources. in subacromial impingement syndrome, shoulder pain affects the quality of life negatively by affecting upper extremity functions and interrupting night sleep. it is very important to control the pain in order to reduce the loss to the labor force and prevent the pain from becoming chronic. various physical treatment methods such as ultrasound, hot pack, transcutaneous electrical nerve stimulation, etc., and injections or medical agents are recommended. this study aimed to compare the effects of ultrasound (us)-guided in comparison to landmark guided subacromial corticosteroids injection on shoulder range of motion (rom), pain, and functional status in patients with subacromial impingement syndrome (sais).

patients were assigned to two groups: group-1 included patients who received us-guided subacromial corticosteroid injections; group-2 included patients who underwent blind subacromial corticosteroid injections. the primary outcome measure was a visual analog scale. secondary outcome measures were shoulder joint range of motion (rom), shoulder pain and disability index (spadi), the shortened disabilities of the arm, shoulder and hand questionnaire (quick dash).

Eligibility criteria:
inclusion criteria: 1. shoulder posterolateral pain that increased with shoulder abduction, 2. restriction of the shoulder passive and active range of motion (rom), 3. patients with positive neer and hawkins impingement test, 4. patients with sais whose diagnosis was confirmed by magnetic resonance imaging (mri), and 5. patients with sais whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate). exclusion criteria: * patients who received corticosteroid, local anesthetic, hyaluronic acid, and platelet-rich plasma injections in the shoulder in the last one year, * patients who had previous history of surgery or fracture in their thorax, neck, upper extremity or shoulder joint, * patients with a rheumatological, cognitive or psychiatric, central or peripheral neurological disease (stroke, spinal cord injury, brachial plexus injury, etc.), * patients whose mri presented a partial or complete rotator cuff tear, calcific tendinitis or labral tear.
effects of motivational interviewing on risky injecting practices among injecting drug users (idus)

Conditions: HIV; Hepatitis C

Summary: the purpose of this study is to evaluate the effects of a brief motivational intervention in reducing risky injection practices among injecting drug users (idus). the investigators hypothesis is that motivational intervention will be more effective than educational intervention in reducing risky injection practices among idus.

injecting drug users (idus) are among the most vulnerable populations at risk to contract human immunodeficiency virus (hiv) and hepatitis c virus (hcv). among canadian cities, montreal holds one of the higher hiv and hcv contraction rates in the idu population. results from survudi, a population survey among idus conducted in the province of quebec (canada), show that in montreal 18% of idus are infected with hiv and 67% are infected with hcv. the cornerstone of hiv and hcv prevention strategies is to give information on safe injection practices and to make available sterile syringes and other injection equipment. however, the survudi survey reveals that a large proportion of idus recruited in community programs offering sterile injection equipment and information on safe injection practices are still sharing needles with other idus. indeed, it seems that information dissemination and distribution of sterile injection equipment are not sufficient in order to control the hiv and hcv epidemic among idus. as a matter of fact, it is obvious that complementary interventions such as behavioural interventions are required. motivational interviewing is an intervention technique centered on the individual. it aims to enhance intrinsic motivation to change behavior by helping the individual to resolve ambivalence. the scientific literature indicates that brief motivational intervention is a significantly effective intervention in order to reduce drug use problems and other related health problems. furthermore, motivational intervention is well adapted for idus' resistance to change and their difficulties related with involvement in long-term therapeutic process. the present study's hypothesis is that idus assigned to the experimental group (brief motivational intervention) will present a greater diminution of their risky injection practices in comparison with idus assigned to the control group (educational intervention).

Eligibility criteria:
inclusion criteria: * in the last month, at least one cocaine injection * in the last month, at least one injection with a syringe or another piece of injection equipment that has been used by someone else * 16 years old or more * french speaking * being able to give informed consent

Keywords: vulnerable populations injecting drug users idu risky injecting practices psychotherapy, brief motivational interviewing educational activities clinical trial risk behavior risk reduction behavior
analysis of oculo-motor deficiencies associated with fmr1 gene expression (genetic abnormality predisposing to a neurodegenerative disease)

Conditions: Pre-mutation on FMR1 Gene

Summary: the specific aim of this study is to compare ocular movements abnormalities between males with pre-mutation on frm1 gene (symptomatic or asymptomatic on the motor plan and/or on the cognitive plan), males without the pre-mutation and males with multi-systematized atrophy, in order to identify the neuronal structures implicated in this pathology.

patient will be followed at the nantes hospital during half a day for : * examination of ocular movements * performing neuro-psychological test (mattis) * performing tests with scales of motricity (updrs, crst, icars).

Eligibility criteria:
for patients with premutation on fmr1 gene (30 patients expected): inclusion criteria: * male * \> or equal to 50 years old * ally second or third degree with a child affected of "fragile x" * not living far from nantes so that visits to the nantes hospital can be easy * pre-mutation on fmr1 gene * signed informed consent exclusion criteria: * female * \<50 years old * visual acuteness \< 1/10 * mattis dementia scale \<100 (normal:144) * occurrence, shown by mri (magnetic resonance imaging), of a pathology either ischemic vascular or hemorrhagic or tumoral for patients without pre-mutation on fmr1 gene (10 patients expected): inclusion criteria: * male * \> or equal to 50 years old * ally second or third degree with a child affected of "fragile x" * not living far from nantes so that visits to the nantes hospital can be easy - signed informed consent exclusion criteria: * female * \<50 years old * visual acuteness \< 1/10 * mattis dementia scale \<100 (normal:144) * pre-mutation on fmr1 gene * occurrence, shown by mri, of a pathology either ischemic vascular or hemorrhagic or tumoral for patients with multi-systematized atrophy (10 patients expected): inclusion criteria: * male * \> or equal to 50 years old * not living far from nantes so that visits to the nantes hospital can be easy * "probable" diagnosis of multi-systematized atrophy * signed informed consent exclusion criteria: * female * \<50 years old * visual acuteness \< 1/10 * mattis dementia scale \<100 (normal:144) * occurrence, shown by mri, of a pathology either ischemic vascular or hemorrhagic or tumoral
comparative effects of mulligan straight leg raise technique versus slump stretching on pain, disability and hip range of motion in patients with chronic low back pain.

Conditions: Chronic Low-back Pain

Summary: the goal of this clinical trial is to examine the effect of mulligan straight leg raise versus slump stretching on pain, disability and hip range of motion in patient with low back pain. . convenient sampling technique will be used to enroll the patients. patients will be inquire into basis of pre formulated eligibility criteria. written consent will be taken from each patient before starting interventional sessions. sample size of this study will consist on the participants who will qualify for both inclusion an exclusion criteria. both groups will receive ultrasonic therapy and hot pack therapy as baseline treatment. group a will receive mulligan straight leg raise and group b will receive slump stretching. the assessment of patients will be done at baseline, 4th and 8th week. the outcomes from patients will be calculated by using visual analogue scale (vas), goniometer and odi. the comparison between pre-treatment and post-treatment data will be done after 8th week. data will be analyzed through spss 25.


Eligibility criteria:
inclusion criteria: * patients who have active positive knee extension test(apket). * patient having low back pain for more than 3 months. * patients who have been sitting for three hours. exclusion criteria: * any active infection, tumor, tuberculosis. * history of trauma. * subject with intervertebral disc prolapse.
a multicenter phase 2 study of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) with 17p deletion

Conditions: Chronic Lymphocytic Leukemia With 17p Deletion; Small Lymphocytic Lymphoma With 17p Deletion

Summary: an open-label, single arm, multicenter phase 2 study of the bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletion

this is a multicenter, international, open-label, single arm, phase 2 study designed to evaluate the efficacy and safety of ibrutinib in subjects with relapsed/refractory cll or sll with del 17p. all subjects will receive ibrutinib until disease progression or unacceptable toxicity occurs.

Eligibility criteria:
key inclusion criteria: * documentation of del (17p13.1) * must have relapsed or refractory cll/sll after receiving at least 1 prior line of systemic therapy. * measurable nodal disease by computed tomography (ct) key exclusion criteria: * history or current evidence of richter's transformation or prolymphocytic leukemia * prior hematologic stem cell transplantation \<6 months from study enrollment or any ongoing gvhd * prior exposure to ibrutinib

Keywords: cll sll